

Contents

<i>Foreword</i>	
<i>Joep M. A. Lange, MD, PhD</i>	<i>v</i>
<i>Preface</i>	<i>vii</i>
<i>Contributors</i>	<i>xi</i>
1 Structural Studies on HIV Reverse Transcriptase Related to Drug Discovery <i>David K. Stammers, PhD and Jingshan Ren, PhD</i>	1
2 Zidovudine, Lamivudine, and Abacavir <i>Monica Carten, MD and Harold Kessler, MD</i>	33
3 Stavudine, Didanosine, and Zalcitabine <i>Gail Skowron, MD, Sapna Chowdhry, MD, and Michael R. Stevens, PharmD</i>	77
4 Emtricitabine <i>Gail Skowron, MD, Jeffrey Bratberg, PharmD, BCPS, and Rudi Pauwels, PhD</i>	133
5 Nucleotide Analogs <i>Craig J. Hoesley, MD</i>	157
6 Resistance to Nucleoside and Nucleotide Reverse Transcriptase Inhibitors <i>Nancy Shulman, MD and Mark Winters, MS</i>	179
7 Pharmacokinetics of Reverse Transcriptase Inhibitors <i>Patrick Hoggard, PhD, Stephen Kewin, PhD, Saye Khoo, MD, PhD, and David Back, PhD</i>	209
8 Peripheral Neuropathy Associated With Nucleoside Reverse Transcriptase Inhibitor Therapy <i>Bruce A. Cohen, MD and Russell Bartt, MD</i>	237

9	Mitochondrial Dysfunction and Nucleoside Reverse Transcriptase Inhibitor Therapy: <i>A Pathophysiological Perspective</i>	
	<i>William Lewis, MD</i>	267
10	Mitochondrial Toxicity and Lipodystrophy	
	<i>Grace McComsey, MD</i>	281
11	Nevirapine	
	<i>David Asmuth, MD, and Richard Pollard, MD</i>	303
12	Efavirenz	
	<i>Graeme J. Moyle, MD, MBBS and Brian Conway, MD</i>	345
13	Delavirdine	
	<i>Brian Conway, MD</i>	375
14	Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors	
	<i>F. Ramzi Asfour, MD and Richard Haubrich, MD</i>	401
15	Vertical Transmission of HIV and Therapeutic Interventions	
	<i>Susan Cu-Uvin, MD, Arlene Bardeguez, MD, MPH, and Carla Chibwesha, MSc</i>	425
16	New Reverse Transcriptase Inhibitors in Development	
	<i>Rudi Pauwels, PhD</i>	471
17	Antiretroviral Drugs for Millions	
	<i>Allan Ronald, MD, Elly Katabira, MBBS, and Merle Sande, MD</i>	499
	Postscript	
	<i>Richard Ogden, PhD and Gail Skowron, MD</i>	515
	<i>Index</i>	517